SBA Financing & the Real Cost of Capital

Drugstores and independent pharmacies sit under NAICS code 456110 — Pharmacies and Drug Retailers. The SBA's size standard for this code is $37.5 million in average annual receipts, which means almost every independent operator — dispensing or not — comfortably qualifies as a small business for federal lending programmes.

For acquisitions and build-outs, SBA 7(a) loans are the workhorse product. Lenders will typically finance up to 90% of the purchase price when a founder is buying an existing pharmacy or drugstore, at rates currently running roughly 10.5%–13.5% APR, with the full underwriting-to-funding process taking 45–90 days. For a ground-up drugstore build (no acquisition), general SBA 7(a) and equipment-financing products cover $25,000 to $5 million, at 6.0%–25.0% APR depending on collateral and lender risk appetite.

Lenders underwriting a drugstore deal will ask three questions before anything else: what share of revenue is dispensing versus front-of-store, what the shrinkage and inventory-turn numbers look like, and whether the applicant is opening a new location or buying an established one with a patient/customer base already attached. A business plan that answers those three questions with real numbers — not generic retail boilerplate — moves through underwriting noticeably faster. Our bespoke business plan service builds SBA-formatted financials specifically to answer this line of questioning.

In the UK, the closest equivalent for a founder without an existing pharmacy contract is the Start Up Loans scheme (up to £25,000 per director at 6% fixed, with free mentoring), often stacked with supplier credit terms and asset finance for shopfitting and dispensing equipment once a GPhC premises registration is in hand.

The Drugstore & Independent Pharmacy Market

The global pharmacies and drug stores market was valued at approximately $1.22 trillion in 2025 and is projected to reach $1.29 trillion in 2026, a compound annual growth rate of roughly 5.8% (The Business Research Company, 2026). The US slice of that market — retail pharmacy specifically — was valued at $676.08 billion in 2025, rising to an estimated $708.67 billion in 2026 (Market Data Forecast, 2026). Growth is being driven by rising chronic-disease prevalence, increasing prescription-drug utilisation, and continued expansion of brick-and-mortar pharmacy and drugstore footprints even as digital healthcare adoption remains limited relative to forecasts from five years ago.

The single most important thing a founder researching this market needs to understand is that "drugstore" and "pharmacy" are not interchangeable terms, even though nearly every business plan template you'll find online treats them as one and the same. A pharmacy is a healthcare-focused, licensed dispensing operation. A drugstore is a broader retail category that sells over-the-counter medication, health and beauty aids, cosmetics, personal care items, and convenience goods — and may or may not include an in-house dispensing counter staffed by a licensed pharmacist. This matters enormously for your business plan, because the two formats have almost nothing in common on the cost side: a non-dispensing HABA-format drugstore can open for $27,000–$210,000, while a full dispensing pharmacy build routinely runs $400,000–$800,000. Section 5 below walks through both formats side by side.

National chains — CVS Pharmacy, Walgreens, and Rite Aid — still dominate US shelf space and prescription volume, but all three have closed hundreds of locations since 2023 as they rationalise real estate, which is opening genuine whitespace for independents and regional chains such as Kinney Drugs (New York/Vermont) and Bartell Drugs (Seattle). In the UK, Boots and Superdrug anchor the high street, but independent contractor pharmacies still make up a large share of NHS dispensing volume, particularly outside major cities where consolidation has been slower.

For founders evaluating where to locate, the strongest opportunity right now sits in secondary high streets and suburban strips within a five-minute drive of a closed CVS, Rite Aid, or independent pharmacy — the prescription-transfer opportunity created by a closure is measurable and can be modelled directly into a Year 1 revenue forecast, which is exactly the kind of detail our market research and content package builds out for clients.

The UK picture tells a similar consolidation story. Pharmacy market revenue in the UK reached approximately £37 billion in 2024 and is projected to grow to around £45 billion by 2029 (Statista, 2025). At the same time, the number of open community pharmacies in England fell from 10,554 in 2024 to 10,407 at 31 March 2025 — even as those remaining pharmacies dispensed a record 1.16 billion prescription items in 2024/25, a 4% increase year over year (NHS Business Services Authority, 2025). In plain terms: fewer pharmacies are absorbing more volume, which is exactly the whitespace-and-transfer dynamic that makes a well-located new entrant — dispensing or OTC/HABA-only — viable in areas where a nearby closure has left patients and shoppers without a convenient alternative.

Consumer behaviour is shifting the front-of-store side of the business too. Shoppers are increasingly comfortable buying OTC medication, vitamins, and personal care items online, but health and beauty aids purchased on impulse or under time pressure — a headache remedy, a plaster, a pregnancy test — still overwhelmingly convert in person. That split is the reason most successful independents now run a hybrid model: a physical footprint sized for convenience and dispensing, supported by click-and-collect or local delivery for repeat/maintenance medication rather than trying to compete head-on with pure e-commerce players on price for one-off purchases.

What It Actually Costs to Open the Doors

Startup capital for a drugstore business spans an unusually wide range — $27,000 to $800,000 (£21,000 to £630,000) — because it depends entirely on whether you're opening a non-dispensing OTC/HABA-format store or a full-service drugstore with a licensed dispensing pharmacy counter. Treat these as two separate budgets, not one sliding scale.

Non-Dispensing Drugstore (OTC/HABA Format)

• Branding, signage & window dressing: $9,000–$52,000 (£7,000–£41,000)
• Security & CCTV systems: $5,000–$46,000 (£3,000–£36,000)
• Insurance (stock, liability, property): $4,000–$31,000 (£3,000–£24,000)
• Shelving, display units & fixtures: $2,000–$29,000 (£1,000–£22,000)
• Retail POS hardware & software: $3,000–$16,000 (£2,000–£12,000) — non-dispensing formats typically run on general retail platforms such as Lightspeed or Square for Retail rather than a full pharmacy management system
• Opening inventory (OTC, HABA, convenience): $2,000–$12,000 (£1,000–£9,000)
• Store lease deposit & shop fit-out: $2,000–$24,000 (£1,000–£19,000)

Full-Service Drugstore With Dispensing Counter

• Dispensing fixtures, equipment & security installations: $75,000–$125,000 (£60,000–£100,000)
• Pharmacy management system, POS & online platform integration: $25,000–$50,000 (£20,000–£40,000) — dispensing-specific platforms such as PioneerRx and BestRx are the two most widely used pharmacy management systems among US independents
• Prescription dispensing equipment specifically: ~$40,000 (£32,000)
• Opening inventory (prescription + OTC combined): $100,000–$250,000 (£80,000–£200,000)
• Working capital reserve (3–6 months): $50,000–$150,000 (£40,000–£120,000)

Funding Routes

In the US, most non-dispensing founders combine personal savings with a small SBA 7(a) loan or equipment financing line; full dispensing build-outs and acquisitions lean much more heavily on SBA 7(a) financing (see the section above) because the capital requirement is simply too large for savings alone. In the UK, the Start Up Loans scheme covers the non-dispensing format comfortably; a full GPhC-registered pharmacy typically needs commercial bank lending or a pharmacy-specialist lender once the NHS contract is secured, since lenders want to see the contract in place before releasing the larger tranche of capital.

Whichever format you choose, budget separately for inventory shrinkage. The industry-standard shrinkage rate for drugstores runs 1–2% of inventory annually from theft, damage, and administrative error — a figure that should appear as its own line in your financial model rather than being buried inside "cost of goods sold," because lenders will ask about it directly.

Named Wholesale Suppliers Worth Opening Accounts With

Your business plan's supply chain section should name actual distributors, not "a wholesale supplier." In the US, three distributors — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — handle the large majority of pharmaceutical distribution nationally, and any dispensing drugstore will need a primary wholesale agreement with one of them, typically backed by a personal guarantee and a credit line sized to roughly one month of expected purchases. For the OTC/HABA side of the business, independents commonly supplement primary wholesale supply with secondary/generic distributors and direct manufacturer accounts to protect margin on fast-moving lines.

Vendor credit terms are worth negotiating into the financial model explicitly rather than assuming cash-on-delivery. Primary pharmaceutical wholesalers typically extend 30-day payment terms once a credit history is established, which effectively finances a meaningful slice of working capital once the store is trading — but a brand-new account with no trading history usually starts on shorter terms, or requires a security deposit, until 3–6 months of payment history builds trust. Your opening working-capital line should assume the tighter terms for the first two quarters and the more favourable 30-day terms from month seven onward; lenders reviewing the forecast will notice if that transition isn't modelled.

In the UK, the equivalent primary distributors are AAH Pharmaceuticals, Alliance Healthcare (also part of the Cencora group), and Phoenix Healthcare Distribution. A new GPhC-registered pharmacy will typically open an account with one as primary supplier and a second as a same-day backup line for out-of-stock items — a detail worth including explicitly in your operations plan, since lenders reviewing a pharmacy acquisition or build-out will specifically ask how supply continuity is protected if the primary wholesaler has a service disruption.

Where the Money Comes From: Revenue & Margin Reality

Revenue in a full-service drugstore comes from two very different economics running side by side under one roof. Prescription dispensing generates most of the transaction volume but very thin per-unit profit: gross profit per prescription typically runs $10–$15, and after reimbursement pressure, staffing, and overhead, net profit per script is usually only $2–$7. Blended prescription margins have fallen to roughly 19.7% industry-wide as payer reimbursement rates have compressed year over year. Front-of-store retail — OTC medication, health and beauty aids, cosmetics, and convenience goods — carries a much healthier 35–50% gross margin, and generic prescription fills (30–45% margin) sit well above brand-name fills (10–15% margin).

Worked example: a store filling 180 prescriptions a day at an average $12 gross profit per script generates roughly $2,160 a day, or about $788,400 a year, from dispensing alone. Layer in front-of-store OTC and HABA sales at a 40% blended gross margin and a full-service independent typically lands near the reported industry median of $994,548 in annual revenue. After labour, rent, and inventory losses, that translates to a net profit margin of just 0.26%–3% for the dispensing model — which is why front-of-store merchandising discipline, not prescription volume, is usually what separates a marginal independent from a genuinely profitable one.

Non-dispensing OTC/HABA-format drugstores run a simpler, higher-margin model precisely because they carry none of the reimbursement risk: net margins of 5–20% are typical once the store is established, with break-even reached faster — usually within 12–18 months versus 18–30 months for a full dispensing operation. Additional revenue streams worth modelling on top of core sales include private label and store-brand OTC lines (which typically carry 10–15 points more margin than branded equivalents), seasonal and convenience merchandise, photo/print services, and — where licensing allows — basic clinical services such as vaccinations and health screenings, which several independent pharmacy groups now use to offset falling dispensing margins.

Basket Size & Repeat-Purchase Economics

Average front-of-store basket size for a drugstore typically runs $8–$15 per transaction in the US ((£6–£12 in the UK), well below a grocery basket but with materially better gross margin per item. The real value driver isn't basket size, though — it's visit frequency. A customer collecting a monthly maintenance prescription visits roughly 12 times a year whether or not they buy anything else, and every one of those visits is a front-of-store cross-sell opportunity a pure e-commerce competitor doesn't get. Independents that actively merchandise around the pickup counter — seasonal health items, impulse HABA products, a loyalty or reward scheme tied to prescription refills — consistently report higher front-of-store attach rates than those that treat the dispensing counter as a separate transaction from the rest of the store. Modelling this attach rate explicitly, rather than assuming a flat front-of-store revenue number, is one of the clearest signals to a lender that the forecast reflects how the business will actually run day to day.

Staffing & Payroll Assumptions

Labour is typically the single largest controllable cost line after inventory. A non-dispensing OTC/HABA store can operate with 2–4 retail staff on rotating shifts, keeping payroll to roughly 12–18% of revenue. A full-service dispensing drugstore needs, at minimum, one licensed pharmacist (either the owner or a hired pharmacist-in-charge), one or two pharmacy technicians, and front-of-store retail staff — pushing payroll toward 20–28% of revenue once benefits and the pharmacist's salary are included. US independent pharmacist salaries typically run $120,000–$140,000 a year depending on region, which is the single biggest reason net margins compress so much once dispensing is added; in the UK, a locum or employed pharmacist typically costs £50,000–£65,000 annually plus National Insurance. Any credible drugstore business plan needs a staffing table that shows headcount by role, ramping in step with prescription and footfall volume rather than hiring the full team from day one.

Two Ways to Build a Drugstore — Which Fits Your Capital?

Before you write a word of the plan, decide which of these three models you're actually building. Lenders, landlords, and your own financial forecast all depend on getting this right first.

Most first-time founders underestimate how viable the OTC/HABA-only route is as a starting point. It requires no pharmacist-in-charge, no DEA registration, and no NHS contract negotiation — which means you can be trading, generating cash flow, and building a customer base months before a full dispensing licence would even clear inspection. The case study below shows exactly this phased approach in practice: OTC/HABA in year one, dispensing counter added in year two once the location and footfall were proven.

A hybrid path worth flagging for founders with limited starting capital: many successful independents join a pharmacy buying group or franchise-style affiliation (in the US, networks such as Health Mart-style community pharmacy groups; in the UK, symbol groups tied to a wholesaler) purely for the improved generic-drug purchasing terms and marketing support, while remaining independently owned and operated. This doesn't reduce the licensing burden, but it meaningfully improves margin on the generic-fill side of the business, which is where most of the dispensing profit actually lives.

Which model is right for you usually comes down to two questions: how much capital you can raise without a pharmacy contract already secured, and how quickly you need the business cash-flow positive. Founders with under $250,000 (£200,000) in available capital and no existing pharmacist relationship almost always do better starting OTC/HABA-only and adding dispensing once the location is proven — the Leeds case study below follows exactly this path. Founders acquiring an existing pharmacy with a transferable patient book and an established NHS contract or third-party payer relationships are the exception: in that case, going straight to full-service from day one is usually the right call, because the revenue base already exists and the main risk is financing the purchase, not building demand from zero.

Think about the exit path too, even at the planning stage. A dispensing pharmacy with an established patient book and payer contracts is a materially more liquid asset than a pure OTC/HABA store when it comes time to sell or bring in a partner — buyers and lenders both value the recurring, insurance-backed revenue that dispensing generates, even though it carries thinner margins day to day. If a future sale or partner buy-in is part of your thinking, it's worth modelling the dispensing counter as a value-creation milestone in the plan, not just a cost centre, since that's genuinely how acquirers in this space price a deal.

Licensing, Registration & Compliance by Country

Regulatory requirements diverge sharply depending on whether you're dispensing prescription medication. A non-dispensing drugstore needs a standard retail business licence in every jurisdiction below; a dispensing counter adds a second, much heavier layer of approval.

United States

• Standard retail business licence — required for any drugstore, dispensing or not
• State pharmacy/drug retailer licence (State Board of Pharmacy) — required only if dispensing; application fee, surety bond, and proof of insurance, cost and process varying by state
• National Provider Identifier (NPI) via CMS/NPPES — free, required for HIPAA compliance once dispensing
• DEA controlled substances registration — required if dispensing controlled substances; renewed every 3 years
• Nonprescription/OTC drug retailer registration — low-cost, state-dependent

United Kingdom

• Standard companies house/sole trader registration and public liability insurance — required for any drugstore
• General Pharmaceutical Council (GPhC) premises registration — required only if dispensing; approximately £590 application fee and £365 annual renewal, with inspection taking up to 3 months
• NHS Community Pharmacy Contract (the "pharmaceutical list"/market entry test, administered via your local Integrated Care Board) — a separate, sequential approval after GPhC registration, typically taking 3–6 months

Canada

Pharmacy premises and pharmacist licensing in Canada is provincial, not federal — each province's College of Pharmacists (Ontario College of Pharmacists, College of Pharmacists of British Columbia, and equivalents elsewhere) administers its own registration process. Foreign-trained pharmacists must pass the PEBC Evaluating and Qualifying examinations, and every dispensing location requires a licensed pharmacist-in-charge on-site. Provinces reference the national NAPRA framework for consistency, but the actual licence is always issued provincially.

A practical timeline note that trips up almost every first-time founder: GPhC/state-board premises registration and the NHS contract/DEA controlled-substances registration are two separate, sequential approvals, not one combined step. Budget your opening timeline — and your business plan's cash-flow forecast — around both stages landing back to back, not simultaneously.

Insurance, Bonding & Premises Compliance

Beyond the licences above, every format needs standard commercial coverage: general liability, property/contents, and workers' compensation (US) or employer's liability insurance (UK) once you have staff. Dispensing operations add professional indemnity or pharmacist's liability cover, and several US states require the surety bond mentioned earlier to be renewed annually alongside the state pharmacy licence. Premises fit-out should also be checked against local zoning (commercial pharmacy/retail use is not automatic in every zone) and, in the US, ADA accessibility requirements for the dispensing counter and any consultation area — an inspection failure on either point is one of the more common causes of an opening date slipping by 4–8 weeks. None of this is exotic, but a business plan that names the actual coverage types and the state/council department responsible for zoning sign-off reads as materially more credible to a lender than one that says "appropriate insurance will be obtained."

Five Mistakes That Sink First-Time Drugstore Owners

We've reviewed enough drugstore and pharmacy business plans to see the same five errors recur, almost regardless of format, location, or founder background. None of them are exotic — they're the kind of gaps that only become visible once a lender, GPhC inspector, or SBA underwriter starts asking follow-up questions the plan didn't anticipate.

• Modelling revenue on dispensing alone. With script margins compressed to roughly 19.7%, a forecast that ignores the 35–50% margin available on front-of-store OTC and HABA product will understate real profitability — or, worse, overstate it if front-of-store sales never materialise because the merchandising plan was an afterthought.
• Assuming "drugstore" automatically means a pharmacist-staffed dispensing counter. Founders routinely over-capitalise on dispensing infrastructure before validating whether local demand actually supports an OTC/HABA-only launch first.
• Under-budgeting for shrinkage. The 1–2% industry-average shrinkage rate needs its own line in the financial model and its own security/inventory-control budget — stores that skip this in the startup budget routinely land above the industry average within the first year.
• Single-sourcing wholesale supply. Opening accounts with only one pharmaceutical or HABA distributor leaves no fallback if that distributor changes terms, has a supply disruption, or simply won't extend the credit terms a new store needs.
• Treating licensing as one step instead of two. GPhC/state-board premises registration and the NHS contract/DEA registration are sequential, not simultaneous — plans that budget a single 60-day licensing window are almost always wrong by a factor of two or three.

Every one of these is fixable at the planning stage. None of them are fixable six months into trading, which is exactly why lenders and investors read the operational detail in a business plan as closely as they read the numbers. A financial model that gets the dispensing/OTC split right, budgets a realistic shrinkage line, names a backup supplier, and lays out the licensing timeline in two stages instead of one is, in practice, the difference between an SBA underwriter approving a loan in 45 days and asking three rounds of clarifying questions that stretch the process to four months.

Inside the Plan: Sample Extract

Here's an extract from a real drugstore business plan written by our team, so you can see exactly what you'll get:

Everything Included in Your Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and regulatory landscape
• Customer Analysis — Target demographics, pain points, and spending patterns
• Competitor Analysis — Local competitive mapping and your differentiation strategy
• Marketing Plan — Channels, messaging, and customer acquisition strategy
• Operations Plan — Day-to-day workflows, staffing structure, and key milestones
• Management Team — Founder bios, advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements — formatted the way SBA and GPhC-registered pharmacy lenders expect to see it, including a separate dispensing-versus-OTC revenue split. If you're still deciding between the OTC/HABA and full-service formats covered above, our business plan writing service can model both scenarios side by side before you commit capital to either one.

Because "drugstore" covers two genuinely different business models, we tailor the Industry Analysis and Operations Plan sections differently depending on which format your plan is built around. An OTC/HABA-only plan focuses the Industry Analysis on front-of-store retail trends and the Operations Plan on merchandising, footfall, and inventory turn. A full-service plan adds a dedicated dispensing-economics subsection covering script volume, payer mix, and reimbursement assumptions, plus a staffing table that reflects the pharmacist-in-charge requirement — the same structure our team used for the phased Leeds launch above, where the Year 1 plan and the Year 2 dispensing addendum were built as two connected but distinct forecasts rather than one blended document.

Frequently Asked Questions

Related Business Plan Templates

Planning something adjacent to a drugstore? These related templates may be a closer fit:

• Vitamin & Supplement Store Business Plan Template — for a HABA-focused format without dispensing
• Digital Pharmacy Business Plan Template — for an online-first dispensing model
• Free Business Plan Template Hub — browse every free template Avvale offers